Skip to main content
Pharmaron Beijing Co., Ltd. logo

Pharmaron Beijing Co., Ltd. — Investor Relations & Filings

Ticker · 300759 ISIN · CNE100003JW4 LEI · 300300JYXHGVS5SNGG54 Shenzhen Stock Exchange Professional, scientific and technical activities
Open in API
Filings indexed 1,320 across all filing types
Latest filing 2026-01-27 Capital/Financing Update
Country CN China
Listing Shenzhen Stock Exchange 300759

About Pharmaron Beijing Co., Ltd.

https://www.pharmaron.cn

Pharmaron Beijing Co., Ltd. is a premier R&D service provider for the life sciences industry, offering a comprehensive, fully integrated platform for drug discovery, development, and manufacturing. The company supports global pharmaceutical and biotechnology partners through a wide range of services, including laboratory chemistry, biology, DMPK, pharmacology, and safety assessment. Its capabilities extend to clinical development services and commercial-scale manufacturing for small molecules, biologics, and cell and gene therapies. By leveraging advanced technology and a global network of facilities, the company facilitates the transition of drug candidates from initial concept to market approval, optimizing the efficiency and success of the drug development lifecycle.

Recent filings

Filing Released Lang Actions
关于2022年A股限制性股票激励计划第三个归属期归属结果暨股份上市的公告
Capital/Financing Update Classification · 95% confidence The document is a detailed announcement from 康龙化成 (Kanglong Huacheng) regarding the 2022 A-share restricted stock incentive plan, specifically the third vesting period's vesting results and the listing of shares. It includes extensive information about the stock incentive plan, including grant prices, quantities, vesting schedules, performance conditions, adjustments, and legal opinions. The document also reports on the board and supervisory meetings approving these matters, the actual vesting numbers, and the impact on share capital and shareholder structure. The document is lengthy (13,890 characters) and contains substantive details about the stock incentive plan implementation and vesting results, not merely an announcement of a report or a brief summary. It is not a general regulatory filing, nor a report publication announcement. It is not a remuneration report but relates to stock incentives and their vesting. The content fits best under the category of Capital/Financing Update (CAP), as it concerns changes in capital structure due to restricted stock vesting and issuance to employees under an incentive plan. Therefore, the filing type code is CAP with high confidence.
2026-01-27 Chinese
关于2021年A股限制性股票激励计划第四个归属期归属结果暨股份上市的公告
Board/Management Information Classification · 95% confidence The document is a detailed announcement regarding the 2021 A-share restricted stock incentive plan of Kanglong Huacheng (Beijing) New Drug Technology Co., Ltd. It includes extensive information about the stock grant, vesting periods, performance conditions, adjustments, and the results of the fourth vesting period including the number of shares vested, the number of participants, and the listing date of the shares. It also includes details about board meetings approving the plan and vesting results, and an auditor's capital verification report. The document is not a full annual or interim financial report, nor is it a simple announcement of a report publication. It is a comprehensive disclosure about the stock incentive plan and its vesting results, which is a form of management and board information related to share-based compensation and executive incentives. This type of document fits best under the category of Board/Management Information (MANG), as it involves board resolutions, management incentive plans, and related disclosures. The document length and detail confirm it is not a brief announcement or a regulatory filing fallback. Therefore, the classification is MANG with high confidence.
2026-01-27 Chinese
H股公告
Share Issue/Capital Change Classification · 100% confidence The document is a disclosure report related to changes in issued shares and treasury shares of a listed company, specifically referencing compliance with Hong Kong Stock Exchange Listing Rules (Main Board and GEM). It details share issuance, shareholding changes, and confirmations related to share transactions. The document is structured as a regulatory disclosure form (FF305) for share capital changes, including issuance and repurchase disclosures. It is not a full financial report, earnings release, or management discussion, but a regulatory announcement of share capital changes. Given the content and regulatory references, the document fits best under the category of Share Issue/Capital Change (SHA). The document length is about 3,000 characters, which is consistent with a regulatory announcement rather than a full report.
2026-01-22 Chinese
关于根据一般发行授权完成配售新H股的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement regarding the completion of a placement of new H shares under a general issuance authorization approved at the 2024 Annual General Meeting. It details the number of shares placed, the pricing, the use of proceeds, and the impact on the company's shareholding structure. The document is relatively short (1719 characters) and serves as a formal notice of a capital raising event rather than a full financial report or detailed presentation. It does not contain comprehensive financial statements or management analysis but focuses on the capital issuance and shareholding changes. Therefore, it fits best under the category of Capital/Financing Update (CAP).
2026-01-22 Chinese
关于实际控制人及其一致行动人持股比例被动稀释权益变动触及1%的公告
Major Shareholding Notification Classification · 95% confidence The document is an announcement regarding a change in shareholding proportions due to an increase in total shares from a new H-share allotment, causing passive dilution of the controlling shareholder's stake. It details the shareholding percentages before and after the event, the nature of the shares, and confirms no change in control or governance. The document is titled as an announcement and contains no financial statements or detailed financial analysis. It is a notification of a change in major shareholding levels, specifically triggered by a share issuance event leading to dilution. Therefore, it fits the category of Major Shareholding Notification (MRQ). The document length and content confirm it is not a brief report publication announcement or a regulatory filing. Confidence is high due to clear alignment with the MRQ definition.
2026-01-22 Chinese
关于根据一般发行授权配售新H股的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement by 康龙化成（北京）新药技术股份有限公司 regarding a new issuance of H shares under a general issuance authorization approved at the 2024 Annual General Meeting. It details the terms of the share placement, including the number of shares, pricing, use of proceeds, impact on shareholding structure, and regulatory approvals required. The document is focused on capital raising through a share placement and does not contain financial statements or detailed financial performance data. It is not a full annual or interim report, nor an earnings release or management discussion. The content aligns with updates on company fundraising and capital structure changes. Therefore, the document fits the category of Capital/Financing Update (CAP). The document length is sufficient and contains detailed information about the financing event, supporting a high confidence classification.
2026-01-15 Chinese

Browse filings by year

8 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.